Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jacek Marek Antas Insider Profile
4 Followers
Jacek Marek Antas, Director at Helix BioPharma, holds 3.19M shares in Helix BioPharma (Ticker: TSE:HBP). Most recently, Jacek Marek Antas Bought C$1,100,000 shares of Helix BioPharma on Nov 09, 2022 for an estimated value of 198.00K.
Jacek Marek Antas has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Jacek Marek Antas's holdings
Insider Roles
Director
Roles that Jacek Marek Antas holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Jacek Marek Antas
Jacek Marek Antas's Trading History
List of latest transactions for each holding click on a transaction to see Jacek Marek Antas's performance on stock
You May Also Like
Jacek Marek Antas insider profile FAQ
What is the percentage of profitable transactions made by Jacek Marek Antas?
The percentage of profitable transactions made by Jacek Marek Antas is ―.
What is the average return per transaction made by Jacek Marek Antas?
The average return per transaction made by Jacek Marek Antas is ―.
What stocks does Jacek Marek Antas hold?
Jacek Marek Antas holds: TSE:HBP stocks.
What was Jacek Marek Antas’s latest transaction?
Jacek Marek Antas latest transaction was an Informative Buy of C$198.00K.
What was Jacek Marek Antas's most profitable transaction?
Jacek Marek Antas’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Jacek Marek Antas's role in Helix BioPharma?
Jacek Marek Antas's role in Helix BioPharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.